We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF

143 hedge funds and large institutions have $516M invested in VanEck Pharmaceutical ETF in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital inflows, than outflows

Capital inflows: $127M | Capital outflows: $101M

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

12.35% more ownership

Funds ownership: 75.6% → 87.95% (+12%)

12% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 42

0% more funds holding

Funds holding: 143 → 143 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

71% less call options, than puts

Call options by funds: $1.25M | Put options by funds: $4.37M

Holders
143
Holders Change
–
Holders Change %
0%
% of All Funds
1.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
31
Increased
47
Reduced
42
Closed
27
Calls
$1.25​M
Puts
$4.37​M
Net Calls
-⁠$3.12​M
Net Calls Change
-⁠$3.62​M

PPH Hedge Fund Activity: Q4 2024 in Review

143 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2024, worth a combined $516M — down 5.3% from $545M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PPH positions and 27 closed out — a net gain of 4 holders — while 47 added to existing stakes and 42 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $17.6M. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $23.6M sold.

  • 143 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $516M of VanEck Pharmaceutical ETF stock for Q4 2024, down 5.3% quarter-over-quarter.
  • 31 funds opened new VanEck Pharmaceutical ETF positions in Q4 2024 and 27 closed out, a net change of +4 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2024 was Goldman Sachs, an estimated $17.6M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2024 was Mirae Asset Global Investments, an estimated $23.6M sold.

Based on aggregated 13F filings for Q4 2024.